Disclaimer: We may earn a commission if you make any purchase by clicking our links. Please see our detailed guide here.

Follow us on:

Google News

Cancer Startup Tempus Gets a $3.1b Valuation, Raises Fresh $200m

Varun Kesari
Varun Kesari
Blogger | Youtuber | Music lover | Tech enthusiastic | Proud To be INDIAN

Join the Opinion Leaders Network

Join the Techgenyz Opinion Leaders Network today and become part of a vibrant community of change-makers. Together, we can create a brighter future by shaping opinions, driving conversations, and transforming ideas into reality.

Malignant growth informatics and accuracy medication organization Tempus said today that it had landed $200 million out of a Series F speculation around. This new round brings the four-year-old company’s absolute funding to $520 million and valuation to $3.1 billion.

The organization reported the financing round on Thursday, alongside designs to extend its clinical information to enable doctors to treat more maladies. Tempus will run a test case program to help patients determined to have melancholy and diabetes next.

Tempus has assembled a library of clinical information close by a working framework to make the information valuable for clinicians and analysts alike. The organization utilizes AI, cutting edge sequencing, and computerized reasoning helped picture acknowledgment to empower logical revelation and help doctors settle on continuous choices to manage the treatment of their patients.

Established in 2015, Tempus is clinical information that consolidates AI, quality sequencing and AI-helped picture acknowledgment to furnish doctors with experiences. Doctors are then ready to utilize that information to customize treatment plans for individual patients, in light of their quality profiles and other significant information. Tempus additionally has a sequencing research center in its rambling Chicago central station.

Tempus CEO and Founder Eric Lefkofsky told GenomeWeb late last year that the company was starting to move into diabetes sectors.

“From our founding, Tempus has been singularly focused on improving the lives of patients diagnosed with the disease, starting with cancer,” Lefkofsky said in a new statement today. “Three and a half years later, we are empowering stakeholders across healthcare with insights derived from real-world clinical evidence connected to rich molecular data.”


Partner With Us

Digital advertising offers a way for your business to reach out and make much-needed connections with your audience in a meaningful way. Advertising on Techgenyz will help you build brand awareness, increase website traffic, generate qualified leads, and grow your business.

Power Your Business

Solutions you need to super charge your business and drive growth

More from this topic